Skip to main content
padlock icon - secure page this page is secure

Mild AKI is associated with mortality of patients who underwent cardiopulmonary bypass surgery

Buy Article:

$42.00 + tax (Refund Policy)

Acute kidney injury (AKI) stage I is the most common stage of AKI observed among patients who underwent cardiac surgery with cardiopulmonary bypass (CPB). The relationship between AKI stage I and mortality requires further investigation. Patients aged 18 years or older who underwent cardiac surgery with CPB between July 1, 2013 and May 31, 2014, were reviewed in the present study. Patients were dichotomized into: i) The AKI stage I group, and ii) the nonAKI group. The primary measured characteristic in the present study was the relationship between AKI and mortality. KaplanMeier survival analyses were taken to obtain survival curves. A total of 1,846 patients were included in this present study. The mean age was 51.76±13.56 years. A total of 1,508 patients did not develop AKI and 338 developed AKI stage I. The mean followup period among survivors was 9.95±3.45 months. KaplanMeier survival analyses showed that patients with AKI stage I were at an increased mortality risk (P<0.0001). In multivariate Cox regression analysis, AKI stage I remained independently associated with a reduced survival. Using a subgroup analysis, patients with nonrecovery AKI (defined as nonrecovery AKI if the serum level does not return before surgery) had a higher mortality rate than patients with recovery AKI (P<0.0001). AKI stage I is the most common form of AKI and it is independently related to allcause mortality in patients who underwent cardiovascular surgery with cardiopulmonary bypass.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Department for Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China

Publication date: October 1, 2020

More about this publication?
  • Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.

    All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more